Molecular imaging of macrophage composition and dynamics in MASLD

Macrophage-mediated inflammation contributes to MASH progression and fibrosis; however, liver biopsy is currently the only tool to assess this response. Thus, the development of non-invasive imaging modalities to identify and follow inflammatory activation is an area of need for patient care. In this study, we leverage molecular imaging using PET radiotracers to follow changes in macrophage composition that are related to MASH disease activity. The results in our preclinical model provide important proof of concept evidence that this approach can be used to diagnose MASH and to follow disease activity in response to intervention. Ongoing studies will evaluate the utility of this modality in humans with MASH.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2024-09-16
DOI
https://doi.org/10.1016/j.jhepr.2024.101220
Citations
7
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular imaging of macrophage composition and dynamics in MASLD

Kathleen Byrnes, Hannah Luehmann, Alexandria Li, Deborah Sultan et al.
7 citations
JHEP Reports
Liver Disease Diagnosis and Treatment
2.71
article

Molecular imaging of macrophage composition and dynamics in MASLD

Kathleen Byrnes, Hannah Luehmann, Alexandria Li, Deborah Sultan, Lanlan Lou, Christopher Park, Mandy M. Chan, Christina Fu, Joel D. Schilling, Gyu Seong Heo, Divangana Lahad, Yongjian Liu, Bin Yang, Peter Voller
article en
7 citations

Abstract

Macrophage-mediated inflammation contributes to MASH progression and fibrosis; however, liver biopsy is currently the only tool to assess this response. Thus, the development of non-invasive imaging modalities to identify and follow inflammatory activation is an area of need for patient care. In this study, we leverage molecular imaging using PET radiotracers to follow changes in macrophage composition that are related to MASH disease activity. The results in our preclinical model provide important proof of concept evidence that this approach can be used to diagnose MASH and to follow disease activity in response to intervention. Ongoing studies will evaluate the utility of this modality in humans with MASH.

JHEP ReportsVol. 6(12)
Washington University in St. Louis (US)
National Science Foundation, Alvin J. Siteman Cancer Center, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Biomedical Imaging and Bioengineering
Openalex Percentile: Top 9%
Liver Disease Diagnosis and Treatment
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.